Results 121 to 130 of about 1,066 (152)
International Journal of Molecular Sciences, 2022 Worldwide, approximately 27 million people are affected by Alzheimer’s disease (AD). AD pathophysiology is believed to be caused by the deposition of the β-amyloid peptide (Aβ). Aβ can reduce long-term potentiation (LTP), a form of synaptic plasticity that is closely associated with learning and memory and involves postsynaptic glutamate receptor ...
Damiana Leo, Laurence Ris, Agnes Villers
exaly +7 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Neuroscience and Biobehavioral Reviews, 2021
There is a need for innovation with respect to therapeutics in psychiatry. Available evidence indicates that the trace amine-associated receptor 1 (TAAR1) agonist SEP-363856 is promising, as it improves measures of cognitive and reward function in schizophrenia.
Jocelyn K Tamura +2 more
exaly +3 more sources
There is a need for innovation with respect to therapeutics in psychiatry. Available evidence indicates that the trace amine-associated receptor 1 (TAAR1) agonist SEP-363856 is promising, as it improves measures of cognitive and reward function in schizophrenia.
Jocelyn K Tamura +2 more
exaly +3 more sources
Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?
Neuroscience and Biobehavioral Reviews, 2021There are nine subfamilies of TAARs. They are predominantly intracellular, located in the central nervous system and peripherally. They have a role in homeostasis and rheostasis, and also in olfaction. They demonstrate significant cross-talk with the monoamine system and are involved in the regulation of cAMP signalling and K+ channels.
Andre Carvalho +2 more
exaly +3 more sources
Trends in Neurosciences, 2023 Schizophrenia remains a major health burden, highlighting the need for new treatment approaches. We consider the potential for targeting the trace amine (TA) system. We first review genetic, preclinical, and clinical evidence for the role of TAs in the aetiopathology of schizophrenia.
Els F Halff +2 more
exaly +3 more sources
Trace amine associated receptor 1 (TAAR1) modulators: a patent review (2010-present)
Expert Opinion on Therapeutic Patents, 2019Introduction: The greater interest in TAAR1-mediated potential for the treatment of different pathologies, especially those related to CNS disorders, has given a considerable boost to the search for developing TAAR1-selective small molecules.Areas covered: During the last decade, the medicinal chemistry efforts have allowed the yield of various ...
Michele Tonelli, Elena Cichero
openaire +2 more sources
Addiction Biology, 2022
Abstract Alcohol dependence is characterized by the abnormal release of dopamine in the brain reward-related areas. Trace amine-associated receptor 1 (TAAR1) is a G Protein-Coupled Receptor that negatively regulates dopamine neurotransmission and thus is a promising target in the treatment of drug addiction.
Bartosz Adam Frycz +6 more
openaire +2 more sources
Abstract Alcohol dependence is characterized by the abnormal release of dopamine in the brain reward-related areas. Trace amine-associated receptor 1 (TAAR1) is a G Protein-Coupled Receptor that negatively regulates dopamine neurotransmission and thus is a promising target in the treatment of drug addiction.
Bartosz Adam Frycz +6 more
openaire +2 more sources
Naunyn-Schmiedeberg's Archives of Pharmacology
Trace amines are physiologically active amines present in all organisms. They are structurally identical to traditional monoamines and are rapidly metabolized by monoamine oxidases. The mammalian neurological system generates these molecules at rates equivalent to traditional monoamines, but because of their short half-life, they are only observable in
Lokesh Kumar Bhatt
exaly +3 more sources
Trace amines are physiologically active amines present in all organisms. They are structurally identical to traditional monoamines and are rapidly metabolized by monoamine oxidases. The mammalian neurological system generates these molecules at rates equivalent to traditional monoamines, but because of their short half-life, they are only observable in
Lokesh Kumar Bhatt
exaly +3 more sources
European Journal of Pharmacology
Trace amine-associated receptor 1 (TAAR1) agonists have shown potential as therapeutic agents for schizophrenia and other neuropsychiatric disorders. However, it remains unclear whether TAAR1 agonists have anticonvulsant activity. We therefore investigated the effects of TAAR1 agonists on acute seizures induced by continuous intravenous infusion of a ...
Misato Yoshikawa +2 more
openaire +2 more sources
Trace amine-associated receptor 1 (TAAR1) agonists have shown potential as therapeutic agents for schizophrenia and other neuropsychiatric disorders. However, it remains unclear whether TAAR1 agonists have anticonvulsant activity. We therefore investigated the effects of TAAR1 agonists on acute seizures induced by continuous intravenous infusion of a ...
Misato Yoshikawa +2 more
openaire +2 more sources
Journal of Clinical Psychopharmacology, 2022
This continuing education supplement is jointly provided by Medical Education Resources and CMEology. The supplement is supported by an independent educational grant from Sunovion Pharmaceuticals Inc. It was edited and peer reviewed by the Journal of Clinical Psychopharmacology.
openaire +2 more sources
This continuing education supplement is jointly provided by Medical Education Resources and CMEology. The supplement is supported by an independent educational grant from Sunovion Pharmaceuticals Inc. It was edited and peer reviewed by the Journal of Clinical Psychopharmacology.
openaire +2 more sources
Stimulus Specific Adaptation Is Affected in Trace Amine-Associated Receptor 1 (TAAR1) Knockout Mice
Journal of Evolutionary Biochemistry and Physiology, 2022V. M. Knyazeva +6 more
openaire +1 more source